IL21R and neoplasm: The amounts of tumor-infiltrating CD8+ and CD4+ TCR-T were both higher in mice receiving IL-21R-TCR-T than conventional TCR-T (Fig. 5l and Supplementary Fig. 9a), especially in the CD8+ TCR-T subsets with an approximately ten-fold increase in mice receiving IL-21R-TCR-T treatment.